Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05998824 · ClinicalTrials.gov registry record · NA

COVID-19 Vaccination Hesitancy in Adults With Sickle Cell Disease

A NA study of Sickle Cell Disease and COVID-19 Vaccine, sponsored by Duke University.

Completed
Registry status
NA
Development phase
33
Enrollment target
1
Study location

NCT05998824: Completed NA study of Sickle Cell Disease and COVID-19 Vaccine, sponsored by Duke University.

NCT05998824 is a NA study of Sickle Cell Disease and COVID-19 Vaccine that has completed, run by Duke University. The registered enrollment target is 33 participants, below the 293-participant average among 213 other Sickle Cell Disease trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05998824, a NA study of Sickle Cell Disease and COVID-19 Vaccine, has completed, sponsored by Duke University.

COMPLETED
Registry status
NA
Development phase
33 participants
Enrollment target
1
Study location

Study Summary

The goal of this clinical trial is to test an COVID-19 vaccination information video in adults with sickle cell disease. The main questions it aims to answer are why are some adults with sickle cell disease hesitant to receive COVID-19 vaccination and whether a COVID-19 vaccination information video tailored for people with sickle cell disease will reduce vaccine hesitancy. Participants will complete a brief survey before and after watching a short video with information on vaccine safety, efficacy, and the greater impact of COVID-19 infection on people with sickle cell disease.

Primary Outcome

To assess vaccine hesitancy in patients not vaccinated for COVID-19, we will ask participants "how likely are you to get vaccinated for COVID-19 in the future?". Response options will be dichotomized into not hesitant ("likely or somewhat likely") vs neutral vs hesitant ("somewhat unlikely or not likely"). We will also assess vaccine hesitancy for people

Conditions Studied

Sickle Cell Disease COVID-19 Vaccine Vaccine Hesitancy

Interventions

  • BEHAVIORAL SCD-specific COVID-19 vaccination information (SCVI) video

Study Locations (1)

North Carolina

  • Duke Adult Sickle Cell Program - Durham

Trial Details

FieldValue
Enrollment Target 33 participants
Start Date 2023-09-19
Est. Completion 2024-09-30
Phase NA
Duke University

1,725 total trials

What the finished NCT05998824 record still lists

NCT05998824 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 33 participants, a relatively small participant target, below the 293-participant average among 213 other Sickle Cell Disease trials with a reported enrollment target (89% lower).

The record links to 3 conditions, with Sickle Cell Disease appearing as the primary indexed condition, and to 1 intervention - of which SCD-specific COVID-19 vaccination information (SCVI) video is the first listed.

NCT05998824 reports a single indexed study location in North Carolina.

Frequently Asked Questions

What is clinical trial NCT05998824 about?

NCT05998824 is a clinical study titled "COVID-19 Vaccination Hesitancy in Adults With Sickle Cell Disease". The goal of this clinical trial is to test an COVID-19 vaccination information video in adults with sickle cell disease. The main questions it aims to answer are why are some adults with sickle cell disease hesitant to receive COVID-19 vaccination and whether a COVID-19 vaccination information video...

What is the current status of trial NCT05998824?

This trial is currently completed. It is a NA study. The enrollment target is 33 participants. The study started on 2023-09-19. Estimated completion is 2024-09-30.

What conditions does trial NCT05998824 study?

This clinical trial studies the following conditions: Sickle Cell Disease, COVID-19 Vaccine, Vaccine Hesitancy.

What interventions are being tested in trial NCT05998824?

The interventions under investigation include: SCD-specific COVID-19 vaccination information (SCVI) video (BEHAVIORAL).

Who is sponsoring clinical trial NCT05998824?

This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05998824 being conducted?

This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Sickle Cell Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05998824's enrollment target sits among peer trials

33 137th of 213 higher than 77 of 213 other Sickle Cell Disease trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Sickle Cell Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02861898 · 33 participants · Phase 1

    Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma

  • NCT04871607 · 33 participants · Phase 2

    Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma

  • NCT05071937 · 33 participants · Phase 2

    ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer

  • NCT05168618 · 33 participants · Phase 2

    Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer, The AtezoCab Trial

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT05998824, the US trial registry maintained by the National Library of Medicine. NCT05998824 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.